Cargando…

Co-mutations of TP53 and KRAS serve as potential biomarkers for immune checkpoint blockade in squamous-cell non-small cell lung cancer: a case report

BACKGROUND: Unprecedented durable responses are identified in clinical studies to target the signaling of programmed cell death protein-1 (PD-1) as well as its ligand (PD-L1) in patients with squamous-cell non-small cell lung cancer (NSCLC). However, factors predicting the patient subtypes that are...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fang, Cheng, Zhang, Chu, Zhao, Wei-Qing, Hu, Wen-Wei, Wu, Jun, Ji, Mei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6794845/ https://www.ncbi.nlm.nih.gov/pubmed/31619231 http://dx.doi.org/10.1186/s12920-019-0592-6

Ejemplares similares

KRAS and TP53 Mutations in Colorectal Carcinoma
por: Al-Kuraya, Khawla S.
Publicado: (2009)

Prognostic Biomarker TP53 Mutations for Immune Checkpoint Blockade Therapy and Its Association With Tumor Microenvironment of Lung Adenocarcinoma
por: Lin, Xinqing, et al.
Publicado: (2020)

Primary Resistance to Immune Checkpoint Blockade in an STK11/TP53/KRAS-Mutant Lung Adenocarcinoma with High PD-L1 Expression
por: Kwack, Won Gun, et al.
Publicado: (2020)

Unique volatolomic signatures of TP53 and KRAS in lung cells
por: Davies, M P A, et al.
Publicado: (2014)

Survival Prediction of Patients Treated With Immune Checkpoint Inhibitors via KRAS/TP53/EGFR-Single Gene Mutation
por: Liu, Shui, et al.
Publicado: (2022)

KRAS, KIT and TP53 mutations in mother’s and daughter’s gastric cardia adenocarcinomas
por: Gluszek, Stanislaw, et al.
Publicado: (2018)

Analysis of Tp53 Codon 72 Polymorphisms, Tp53 Mutations, and HPV Infection in Cutaneous Squamous Cell Carcinomas
por: Loeb, Keith R., et al.
Publicado: (2012)

The prognostic value of TP53 mutations in hypopharyngeal squamous cell carcinoma
por: Omura, Go, et al.
Publicado: (2017)

KRAS/LKB1 and KRAS/TP53 co-mutations create divergent immune signatures in lung adenocarcinomas
por: Gu, Meichen, et al.
Publicado: (2021)

Induction of pancreatic neoplasia in the KRAS/TP53 Oncopig
por: Mondal, Pinaki, et al.
Publicado: (2023)

Simplified molecular classification of lung adenocarcinomas based on EGFR, KRAS, and TP53 mutations
por: Ruiz-Cordero, Roberto, et al.
Publicado: (2020)

TP53 /KRAS Co-Mutations Create Divergent Prognosis Signatures in Intrahepatic Cholangiocarcinoma
por: Guo, Chunguang, et al.
Publicado: (2022)

Efficient Correction of Oncogenic KRAS and TP53 Mutations through CRISPR Base Editing
por: Sayed, Shady, et al.
Publicado: (2022)

Mutational Analysis of KRAS, BRAF, and TP53 Genes of Ovarian Serous Carcinomas in Korean Women
por: Cho, Yun-Hyun, et al.
Publicado: (2009)

Prognostic value of KRAS/TP53/PIK3CA in non-small cell lung cancer
por: Zhao, Jiayi, et al.
Publicado: (2019)

TP53 and RET may serve as biomarkers of prognostic evaluation and targeted therapy in hepatocellular carcinoma
por: Ye, Song, et al.
Publicado: (2017)

TP53 and RET may serve as biomarkers of prognostic evaluation and targeted therapy in hepatocellular carcinoma
por: Ye, Song, et al.
Publicado: (2022)

TP53-Associated Ion Channel Genes Serve as Prognostic Predictor and Therapeutic Targets in Head and Neck Squamous Cell Carcinoma
por: Sun, Jing, et al.
Publicado: (2020)

Reduction of pericardial effusion in advanced non-small cell lung cancer patients with KRAS, TP53, and MET mutation treated with nivolumab
por: Cai, Zhihui, et al.
Publicado: (2020)

TP53 mutations in vulval lichen sclerosus adjacent to squamous cell carcinoma of the vulva
por: Rolfe, K J, et al.
Publicado: (2003)

Specific TP53 subtype as biomarker for immune checkpoint inhibitors in lung adenocarcinoma
por: Sun, Hao, et al.
Publicado: (2020)

Genetic alterations of KRAS and TP53 in intrahepatic cholangiocarcinoma associated with poor prognosis
por: Peng, Jianbo, et al.
Publicado: (2023)

Correlate the TP53 Mutation and the HRAS Mutation with Immune Signatures in Head and Neck Squamous Cell Cancer
por: Lyu, Haoyu, et al.
Publicado: (2019)

TP53 missense mutation reveals gain-of-function properties in small-sized KRAS transformed pancreatic ductal adenocarcinoma
por: Zhou, Yiran, et al.
Publicado: (2023)

Distribution of KRAS, DDR2, and TP53 gene mutations in lung cancer: An analysis of Iranian patients
por: Fathi, Zahra, et al.
Publicado: (2018)

KRAS and TP53 mutations in inflammatory bowel disease-associated colorectal cancer: a meta-analysis
por: Du, Lijun, et al.
Publicado: (2017)

Mutational status of TP53 defines the efficacy of Wee1 inhibitor AZD1775 in KRAS-mutant non-small cell lung cancer
por: Ku, Bo Mi, et al.
Publicado: (2017)

The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis
por: Leroy, Bernard, et al.
Publicado: (2013)

Mutated TP53 in Circulating Tumor DNA as a Risk Level Biomarker in Head and Neck Squamous Cell Carcinoma Patients
por: Kampel, Liyona, et al.
Publicado: (2023)

ARID1A, ARID1B, and ARID2 Mutations Serve as Potential Biomarkers for Immune Checkpoint Blockade in Patients With Non-Small Cell Lung Cancer
por: Zhu, Guangsheng, et al.
Publicado: (2021)

The High Expression of p53 Is Predictive of Poor Survival Rather TP53 Mutation in Esophageal Squamous Cell Carcinoma
por: Jin, Yan, et al.
Publicado: (2023)

Role of next generation sequencing-based liquid biopsy in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: impact of STK11, KRAS and TP53 mutations and co-mutations on outcome
por: Pavan, Alberto, et al.
Publicado: (2021)

Ntrk1 Promotes Resistance to PD-1 Checkpoint Blockade in Mesenchymal Kras/p53 Mutant Lung Cancer
por: Konen, Jessica M., et al.
Publicado: (2019)

Integrated single-cell RNA-seq analysis identifies immune heterogeneity associated with KRAS/TP53 mutation status and tumor-sideness in colorectal cancers
por: Liu, Xiaoyu, et al.
Publicado: (2022)

TP53 Mutations in Nonsmall Cell Lung Cancer
por: Mogi, Akira, et al.
Publicado: (2011)

TP53 mutations on circulating cell-free DNA
por: Pantel, Klaus
Publicado: (2016)

KRAS Mutations in Squamous Cell Carcinomas of the Lung
por: Acker, Fabian, et al.
Publicado: (2021)

Extremely High Tp53 Mutation Load in Esophageal Squamous Cell Carcinoma in Golestan Province, Iran
por: Abedi-Ardekani, Behnoush, et al.
Publicado: (2011)

Molecular characterisation of TP53 mutated squamous cell carcinomas of the lung to identify putative targets for therapy
por: Haakensen, Vilde D., et al.
Publicado: (2020)

Performance of the pattern‐based interpretation of p53 immunohistochemistry as a surrogate for TP53 mutations in vulvar squamous cell carcinoma
por: Kortekaas, Kim E, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_uvlator4qs0qj8ieval6uae56n